Abbott
Business & Industry
- Bayer invests 130 million EUR in new production facility for innovative parenteral products
- Pfizer and Astellas' XTANDI® approved by U.S. FDA in earlier prostate cancer treatment setting
- Roche's subcutaneous injection of Tecentriq recommended by the EU's CHMP for multiple cancer types
- Bayer and Recursion focus research collaboration on oncology
- Bayer expands global life science incubator network
Research & Development
- AI may spare breast cancer patients unnecessary treatments
- Lidocaine may be able to kill certain cancer cells by activating bitter taste receptors
- Skin bacteria can save lives
- Potential therapeutic target found to combat tuberculosis, a disrupted NAD(H) homeostasis
- Vitamin B12: a key player in cellular reprogramming and tissue regeneration
- UK diabetes prevention program may have global impact
- Artificial intelligence: Unexpected results
Conferences & Events
- SAE Media Group proudly presents the 4th Annual AI in Drug Discovery Conference
- SAE Media Group's 6th annual 3D Cell Culture Conference
- CPHI Frankfurt returns to pre-pandemic strength as pharma industry booms again
- 14th Annual RNA Therapeutics: Investigating the next generation of genetic medicine through RNA based therapies
- CPHI Excellence in Pharma Award Winners 2022
- CPHI Frankfurt Report predicts huge funding overhang to drive contract services growth
- CPHI Frankfurt 2022: Global pharma confidence hits record high in the annual CPHI Pharma Index
Regulatory Affairs
- FDA approves first therapy for rare type of non-cancerous tumors
- First electronic product information (ePI) published for selected human medicines
- FDA approves first treatment for patients with rare inherited blood clotting disorder
- FDA takes action on updated mRNA COVID-19 vaccines to better protect against currently circulating variants
- FDA approves first oral treatment for postpartum depression